Cargill-Cerestar unveils new excipient at CPhI
of a directly compressible excipient platform that allows tablets
to be produced using lower compression forces.
C*PharmMannidex DC is a mannitol-based excipient which enables customers to formulate tablets with higher doses of active ingredients. This is useful where customers are increasing their use of starch-based excipients that are not animal derived.
The product itself is a reduced calorie and non-cariogenic excipient, which is extremely suitable for producing tablets with direct compression. Due to its non-hygroscopic character it is of particular use with moisture sensitive active ingredients.
The excipient shows good compressibility at all compression forces. In addition, the flowability guarantees easy workability.
"Pharmaceutical industry standards therefore require an equivalent degree of commitment to promote health and well-being," said James Taylor, strategic development manager at Cerestar Food & Pharma Specialties
"Linking global research of pharmaceutical requirements is key to developing excipients and customer-specific solutions. All our ingredients are manufactured from non-animal derived agricultural raw materials meeting the highest standards required for pharmaceutical applications."
C*PharmMannidex DC is suitable for parenteral nutrition and intravenous injections - applications requiring products of the high quality. Proof of this has been achieved, meeting all requirements of Ph. Eur., USP / NF and JP, when tested accordingly.
The excipient will feature on Stand E22, Hall 10, at CPhI 2005.
